PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)

Benzer Materyaller

• P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
  Yazar:: A. Vannucchi, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
  Yazar:: Lucia Masarova, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
  Yazar:: Jean-Jacques Kiladjian, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-11-01)
• Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
  Yazar:: Ruben Mesa, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-06-01)
• Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
  Yazar:: Stephen T. Oh, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-02-01)